REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced promising anti-tumor and safety data for RMC-6236, its RASMULTI(ON) Inhibitor, in patients with previously treated non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) across several dose levels and KRASG12X genotypes, including common KRAS-mutant genotypes G12D and G12V.

REDWOOD CITY，CA，2023年10月22日（GLOBE NEWSWIRE）-Revolution Medicines，Inc。（纳斯达克股票代码：RVMD），一家临床阶段肿瘤公司，开发针对RAS成瘾癌症的靶向治疗，今天宣布有希望的抗肿瘤和RMC-6236，其RASmolti（ON）抑制剂的安全性数据，在先前治疗的非小细胞肺癌（NSCLC）和胰腺导管腺癌（PDAC）患者中，在几个剂量水平和KRASG12X基因型，包括常见的KRAS突变基因型G12D和G12V。

These initial results were presented during a Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress in Madrid, October 20-24, 2023. “Today’s presentation marks an important milestone in the clinical development of RMC-6236, an unprecedented, oral RASMULTI(ON) Inhibitor with an innovative mechanism of action.

这些初步结果是在2023年10月20日至24日在马德里举行的欧洲肿瘤内科学会（ESMO）大会上提交的一篇论文中提出的。“今天的演讲标志着RMC-6236临床开发的一个重要里程碑，RMC-6236是一种前所未有的口服RASMULTI（ON）抑制剂，具有创新的作用机制。

The findings reinforce our belief that by inhibiting the (ON), or active, form of diverse RAS cancer drivers, RMC-6236 can lead to meaningful clinical responses in patients at dose levels that are generally well tolerated,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines.

这些发现加强了我们的信念，即通过抑制不同RAS癌症驱动因素的（ON）或活性形式，RMC-6236可以在通常耐受良好的剂量水平的患者中产生有意义的临床反应，“Mark A.Goldsmith，M.D.，博士，首席执行官和革命药物主席。

“These data also confirm that RMC-6236 can target multiple common RAS variants that cause cancer, supporting its ongoing development as monotherapy in patients with NSCLC or PDAC harboring RAS mutations. Further, RMC-6236 has a compelling profile for evaluation in combination treatment strategies with RMC-6291, our mutant-selective RASG12C(ON) Inhibitor, and with immunotherapy and other cancer drugs.” The RMC-6236-001 Phase 1/1b trial is a multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate RMC-6236 as monotherapy in patients with advanced solid tumors harboring KRASG12X mutations.

“这些数据还证实，RMC-6236可以靶向多种常见的导致癌症的RAS变异体，支持其在NSCLC或携带RAS突变的PDAC患者中作为单一疗法的持续发展。此外，RMC-6236在与RMC-6291，我们的突变选择性RASG12C（ON）的联合治疗策略抑制剂，以及免疫疗法和其他癌症药物。”RMC-6236-001 1/1b期试验是一项多中心，开放标签，剂量递增和剂量扩展研究，旨在评估RMC-6236作为携带KRASG12X突变的晚期实体瘤患者的单药治疗。

As of .

截至。